GSTC Stock Overview
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GlobeStar Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0007 |
| 52 Week High | US$0.0081 |
| 52 Week Low | US$0.0006 |
| Beta | 1.55 |
| 1 Month Change | -30.00% |
| 3 Month Change | -22.22% |
| 1 Year Change | -85.11% |
| 3 Year Change | -99.02% |
| 5 Year Change | -90.00% |
| Change since IPO | -99.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| GSTC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -22.2% | 0.5% | -0.7% |
| 1Y | -85.1% | 1.2% | 22.8% |
Return vs Industry: GSTC underperformed the US Biotechs industry which returned 0.1% over the past year.
Return vs Market: GSTC underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| GSTC volatility | |
|---|---|
| GSTC Average Weekly Movement | 32.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GSTC's share price has been volatile over the past 3 months.
Volatility Over Time: GSTC's weekly volatility (32%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Jim Katzaroff | www.globestartherapeutics.com |
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021.
GlobeStar Therapeutics Corporation Fundamentals Summary
| GSTC fundamental statistics | |
|---|---|
| Market cap | US$814.04k |
| Earnings (TTM) | -US$1.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs GSTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSTC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.98m |
| Earnings | -US$1.98m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0017 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -24.5% |
How did GSTC perform over the long term?
See historical performance and comparison